References
- Renoux G. Modulation of immunity by levamisole. Pharmac. Thera. A. 1978; 2: 397
- Griswold D. E., Walz D. T. Condition-dependent imnuno-regulatory control of contact sensitivity by levamisole. Inflammation 1977; 2: 277
- Cunningham F. M., Ford-Hutchinson A. W., Oliver A. M., Smith M. J.H., Walker J. R. The effects of d-penicillamine and levamisole on leukocyte chemotaxis in the rat. Br. J. Pharmacol. 1978; 63: 119
- Cottney J., Bruin J., Lewis A. J. Modulation of the immune system in the mouse. 1. Drug administration prior to antigen sensitization. Agents and Actions 1980; 10: 378
- Cottney J., Bruin J., Lewis A. J. Modulation of the immune system in the mouse, 2. Drug administration following antigen sensitization. Agents and Actions 1980; 10: 48
- Arrigoni-Martelli E., Bramm E., Huskisson E. C., Willoughby D. A., Dieppe P. A. Pertussis vaccine edema: an experimental model for the action of penicillamine-like drugs. Agents and Actions 1976; 6: 613
- Lewis A. J., Parker J., DiLuigi J., Datko L., Carlson R. P. Immunomodulation of delayed hypersensitivity to methylated bovine serum albumin (MBSA) in mice. Fed. Proc. 1981; 40: 990
- Hambleton P., Miller P., Robson E., Smith S. Differential modulation of delayed hypersensitivity. Br. J. Pharmacol. 1980; 70: 1868
- Lewis A. J., DiLuigi J., Parker J., Datko L., Carlson R. P. Wy-18,251 (3-(p-chlorophenyl) thiazole[3,2-a]benzimidazole-2-acetic acid); a novel immunomodulator drug with antiinflammatory properties. Fed. Proc. 1981; 40: 1005
- Fenichel R. L., Alburn H. E., Schreck P. A., Bloom R., Gregory F. J. Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633). J. Immunopharmacol. 1980; 2: 491
- Parrillo J. E., Fauci A. S. Mechanisms of glucocorticoid action on immune processes. Ann. Rev. Pharmacol. Toxicol. 1979; 19: 179
- Cunningham F. M., Ford-Hutchinson A. W., Smith M. J.H., Walker J. R. Effects of d-penicillamine and levamisole on delayed hypersensitivity reactions in the rat and mouse. Br. J. Pharmacol. 1978; 62: 423P
- Dieppe P. A., Willoughby D. A., Huskisson E. C., Arrigoni-Martelli E. Pertussis vaccine pleurisy: a model of delayed hypersensitivity. Agents and Actions 1976; 6: 618
- Arrigoni-Martelli Brauun E.E., Binderup L. Immunostimulant activity of d-penicillamine. Drugs Exptl. Clin. Res. 1977; 2: 189
- Umezawa H., Ishizuka M., Aoyagi T., Takeuchi T. Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J. Antibiotics 1976; 29: 857
- Wooles W. R. Reticuloendothelial function and the immune response. Science 1963; 142: 1078
- Stewart-Tull D. E.S. The immunological activities of bacterial peptidoglycans. Ann. Rev. Microbiol. 1980; 34: 311
- Walz D. T., Griswold D. E. Immunopharmacology of gold sodium thiomalate and auranofin (SK&F D-39162). Inflammation 1978; 3: 117
- Lewis A. J., Walz D. T. The immunopharmacology of gold salts. Progr. Med. Chem., in press
- Borel J. F., Feurer C., Gubler B. V., Stahelin H. Biological effects of cyclosporin A: a new anti-lymphocytic agent. Agents and Actions 1976; 6: 468
- Borel J. F., Feurer C., Magnee C., Stahelin H. Effects of the new antilymphocytic peptide cyclosporin A in animals. Immunology 1977; 32: 1017
- Cashin C. H., Gill J., Jones S. A., Kennedy A. J. An assessment of the delayed hypersensitivity reaction to methylated bovine serum albumin in the mouse and its use in the evaluation of drug effects on cell mediated immune reactions. Agents and Actions 1979; 9: 553
- Shand F. L. The immunopharmacology of cyclophosphamide. Int. J. Immunopharmac. 1979; 1: 165
- Megel H., Raychaudhuri A., Goldstein S., Kinsolving C. R., Shemano I., Michael J. E. Tilorone: its selective effect on humoral and cell mediated immunity. Proc. Soc. Exp. Biol. Med. 1974; 745: 513
- Daniels J. C., Warren K. S., David J. R. Studies on the mechanism of suppression of delayed hypersensitivity by the antischistosomal compound niridazole. J. Immunol. 1975; 115: 1414
- Crowle A. J. Delayed hypersensitivity in the mouse. Adv. Immunol. 1975; 20: 197
- Askenase P. W. The role of basophils, mast cells and vasoamines in hypersensitivity reactions with a delayed time course. Progr. Allergy 1977; 23: 199
- Lewis A. J., Carlson R. P., Dervinis A., Capetola R. J., Rosenthale M. E. The antiallergic activity of Wy-41, 195. Fed. Proc. 1980; 39: 1017
- van Dijk H., Rademaker P. M., Kerkhofs J. P., Willers J. M.N. Histamine 2-receptor-mediated immunomodulation in the mouse. II. Inmunomodulation by the H2 antagonist metiamide. Int. J. Immunopharmac. 1980; 2: 345
- Askenase P. W. Histamine 2-antagonist inhibition of delayed hypersensitivity (DH). Clin. Res. 1977; 25: 481
- Avella J., Madsen J. E., Binder H. J., Askenase P. W. Effect of histamine H2-receptor antagonists on delayed hypersensitivity. Lancet 1978; i: 624
- Gershon R. K., Askenase P. W., Gershon M. D. Requirement for vasoactive amines for production of delayed-type hypersensitivity skin reactions. J. exp. Med. 1975; 142: 732